EMBO Journal APC and Open Access: Full Gold OA at $5,450 Through EMBO Press

The EMBO Journal completed its transition to full gold open access in 2023. This is a permanent shift, not a pilot. Every article published in The EMBO Journal is:

• Immediately free to read upon publication
• Published under a CC BY license (the most permissive Creative Commons option)
• Indexed and accessible through PubMed, PMC, and all standard databases

The practical consequence is straightforward: if your paper is accepted, you will pay the APC. There's no option to publish behind a paywall for free. This is different from hybrid journals like Cancer Cell or Nature Medicine, where subscription-track publication costs nothing.

For researchers on tight budgets without institutional coverage, the mandatory APC is a real consideration when choosing where to submit. But for those at institutions with Springer Nature agreements, the cost is usually covered automatically.

EMBO Press publishes The EMBO Journal, EMBO Reports, EMBO Molecular Medicine, Molecular Systems Biology, and Life Science Alliance. Since 2019, these journals have been published in partnership with Springer Nature, which handles production, distribution, and APC infrastructure.

This partnership is directly relevant to the APC question because it means EMBO Press journals are included in Springer Nature's institutional agreement ecosystem. When your institution negotiates a Read & Publish deal with Springer Nature, EMBO Press titles can be part of that package.

The specifics vary by agreement. Some consortia explicitly include EMBO Press journals in their Springer Nature deals. Others don't. The coverage isn't as uniform as it is for core Nature Research titles, so checking with your library is essential.

The coverage for EMBO Press titles through Springer Nature agreements is good but not universal. The safest approach is to ask your library two specific questions: (1) Does our Springer Nature agreement exist? and (2) Does it include EMBO Press journals? Don't assume that a general Springer Nature deal covers The EMBO Journal automatically.

EMBO Press follows the Springer Nature waiver framework:

• Full waiver: Corresponding authors at institutions in Research4Life Group A countries (low-income nations per World Bank classification).

• 50% discount: Corresponding authors in Group B countries (lower-middle-income nations).

• Hardship waivers: Case-by-case requests are considered. Contact the editorial office after acceptance.

Since The EMBO Journal is fully gold OA with no subscription fallback, the waiver system is particularly important. Without it, researchers at underfunded institutions would be effectively locked out of publishing here. EMBO's commitment to waivers helps maintain accessibility.

EMBO also has its own funding programs for young investigators (EMBO Young Investigator Programme, EMBO Installation Grants) that can be used toward publication costs, though these aren't specific APC subsidies.

The EMBO Journal covers molecular and cell biology broadly, with particular strength in:

• Gene expression and regulation
• Cell signaling and signal transduction
• Chromatin, epigenetics, and genome integrity
• Membrane biology and intracellular trafficking
• Structural biology and biophysics
• Developmental biology at the molecular level
• Immunology and infection at the cellular level

The journal has an impact factor of approximately 9 (2024 JCR). It published roughly 250-300 research articles in 2024. The acceptance rate is estimated at 10-15% of submitted manuscripts, with a desk-rejection rate around 60-65%.

The EMBO Journal is known for a transparent review process. It was an early adopter of published peer review reports, and its editorial model emphasizes constructive referee feedback. Many researchers consider the review experience at EMBO journals to be among the fairest in biomedical publishing.

This is where full gold OA simplifies everything. Because every EMBO Journal article is published OA under CC BY, all funder mandates are automatically satisfied. You don't need to choose a license, request a specific OA option, or arrange a PMC deposit. It's all handled by default.

For NIH-funded researchers, this is a meaningful advantage. Many hybrid journals require you to either pay an APC for gold OA or manually deposit in PMC after an embargo. The EMBO Journal does the deposit automatically because every article is already OA.

The EMBO Journal doesn't charge submission fees, page fees, or color figure charges. But be aware of:

• Tax: VAT applies in many European jurisdictions, adding 15-25% to the listed APC. Since the base price is in EUR, European authors feel this directly.

• Mandatory APC: Unlike hybrid journals, there's no free subscription track. If you're accepted and can't secure waiver coverage or institutional support, you still owe the APC.

• Figure quality standards: EMBO journals have high figure preparation standards. Multi-panel figures with inconsistent formatting or resolution will be flagged during production. Budget time (and potentially money for illustration tools) for proper figure preparation.

• Data availability requirements: The EMBO Journal requires data deposition in public repositories. Genomic data goes to GEO/ArrayExpress, structural data to PDB, proteomics data to PRIDE. These deposits are free but require significant preparation time.

One distinctive feature of The EMBO Journal is its transparent review process. Referee reports and author responses are published alongside accepted articles. This means:

• Readers can see what reviewers questioned and how authors responded
• The review history becomes part of the scientific record
• Authors tend to receive more constructive reviews because referees know their comments will be public

This transparency doesn't affect the APC, but it does affect the publication experience. Many researchers report that EMBO journal reviews are more thoughtful and less adversarial than at comparable journals. The public accountability seems to improve review quality.

For molecular and cell biologists considering The EMBO Journal:

1. Check institutional coverage. Ask your library specifically whether your Springer Nature agreement covers EMBO Press journals.
2. Budget for the mandatory APC. There's no free subscription track. If your institution doesn't cover it, the $5,450 comes from grant funds.
3. Factor in funder compliance. Gold OA with CC BY satisfies all major funder mandates automatically. No extra steps needed.
4. Comparing with Cell Reports? The EMBO Journal has better institutional coverage and a higher impact factor at a similar price. Unless your paper fits Cell Reports' scope better, The EMBO Journal is the stronger choice.
5. Comparing with Molecular Cell? If your paper has the mechanistic depth for Molecular Cell (IF ~16), the higher impact factor may justify the higher cost ($9,350). But if Molecular Cell's coverage gap means you pay out of pocket while The EMBO Journal is covered institutionally, the math favors EMBO.

EMBO editors value mechanistic clarity and clean experimental design. A paper that tells a tight, well-controlled story will do better than one that throws in every possible experiment. EMBO Journal submission readiness check to make sure your manuscript's logic flow and experimental narrative are solid before submitting.

For the latest APC information and author guidelines, visit the EMBO Journal author page.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)
• An institutional Read & Publish agreement covers the fee
• Open access visibility meaningfully benefits your research area
• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense
• A subscription option or green OA (preprint + embargo) satisfies your funder
• Another OA journal with a lower APC would provide similar visibility